Dose Reference Table

Pre-calculated for a 10mg vial + 2ml BAC water = 5,000 mcg/ml concentration. Using a 100-unit (1ml) insulin syringe.

Dose Inject Volume (ml) Syringe Units
1250mcg (1.25mg) 0.250 ml 25 units
2500mcg (2.5mg) 0.500 ml 50 units
5000mcg (5mg) 1.000 ml 100 units
7500mcg (7.5mg) 1.500 ml 150 units
10000mcg (10mg) 2.000 ml 200 units

About Tirzepatide

Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It was developed and is FDA-approved under the brand name Mounjaro for type 2 diabetes and Zepbound for obesity. In research settings, it has attracted interest for its superior weight reduction efficacy compared to GLP-1 monotherapy agents.

Research-grade tirzepatide is commonly supplied in 5mg, 10mg, and 15mg vials. The most practical reconstitution for a 10mg vial is 2ml of bacteriostatic water, yielding 5,000 mcg/ml. At this concentration, doses are expressed in milligrams for convenience: 2.5mg = 0.5ml = 50 units.

Tirzepatide has a half-life of approximately 5 days, supporting once-weekly subcutaneous administration. The recommended escalation schedule typically starts at 2.5mg/week and increases by 2.5mg every 4 weeks up to a maximum of 15mg/week based on tolerability.

Frequently Asked Questions

2ml of bacteriostatic water is the standard for a 10mg tirzepatide vial, giving a concentration of 5,000 mcg/ml. At this concentration, a 2.5mg dose = 0.5ml = 50 units.
Draw 2ml of bacteriostatic water into a fresh insulin syringe. Inject slowly into the tirzepatide vial along the glass wall. Gently swirl until fully dissolved — do not shake. Store at 2–8°C.
For 30mg of tirzepatide (e.g. three 10mg vials combined or a 30mg vial), use 6ml of bacteriostatic water to maintain 5,000 mcg/ml concentration. This gives 6ml total volume.
When reconstituted with bacteriostatic water and refrigerated at 2–8°C, tirzepatide is typically stable for 28–30 days. Do not freeze the reconstituted solution.
Clinically, tirzepatide starts at 2.5mg per week, with dose escalation every 4 weeks. This gradual approach minimizes GI side effects. In research settings, protocols may vary.